Sex differences in procedural characteristics, safety, and clinical outcomes of pulsed field ablation for atrial fibrillation
Year: 2025
Type: article
Abstract: Background Previous studies on pulmonary vein isolation (PVI) for the treatment of atrial fibrillation (AF) using conventional thermal techniques have shown inconsistent sex-related outcomes. Pulsed-field ablation (PFA) is a novel energy source offering myocardial-selective ablation. However, sex-specific data on its performance are limited. Objective To compare procedural characteristics, safety, and clinical outcomes of PFA in female and male patients undergoing AF ablation. Methods This prospective study included consecutive patients with paroxysmal or persistent AF undergoing PFA-based PVI using a pentaspline catheter. Follow-up was conducted at 3, 6, and 12 months. A 1:1 propensity score-matched cohort was created to evaluate sex-specific outcomes. Results Among 425 patients, 134 (32%) were female. Compared to males, females were older (median 70 vs. 65 years; p <.001), had more frequently paroxysmal AF (60% vs. 45%; p =.006), and lower rates of coronary artery disease (CAD, 6% vs. 14%; p =.029). While overall procedural times were similar, female patients with paroxysmal AF had significantly longer procedure, left atrial dwell, and fluoroscopy times than males. Complication rates were comparable (1.5% in females vs. 0.7% in males; p =.371). After propensity score matching (133 females to 133 males), arrhythmia recurrence at 1-year follow-up was higher in females (23% vs. 12%; p =.017; HR 2.2, SE 0.34). Conclusion Significant sex-related differences exist in clinical outcomes after PVI with PFA in AF. Further studies exploring underlying mechanisms and tailored approaches may enhance outcomes in female patients.
Source: Heart Rhythm O2
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,150
Funders: National Science Foundation, Pfizer, AstraZeneca, Foundation for Cardiovascular Research, Universität Basel, Boston Scientific Corporation, Freiwillige Akademische Gesellschaft, ReCor Medical, European Commission, Deutsche Forschungsgemeinschaft, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Schweizerische Herzstiftung, Universität des Saarlandes, Deutsche Herzstiftung, MicroPort, Biosense Webster, Daiichi Sankyo Europe
Awards: G1163105609, G1474430447, G1752643403, G3421341489, G3830373416, Swiss Atrial Fibrillation Cohort Study, G4542678335, Mechanisms of cognitive decline in patients with atrial fibrillation: the Swiss AF-Brain Study, Health Consequences of the Burden of Atrial Fibrillation - The Swiss-AF-Burden study, Swiss Atrial Fibrillation Cohort Study, TRR 219: Mechanismen kardiovaskulärer Komplikationen bei chronischer Niereninsuffizienz
OpenAlex ID: W4415535575
